Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis

被引:0
作者
Jonathan A. Batty
Mengyao Tang
Marlous Hall
Roberto Ferrari
Martin H. Strauss
Alistair S. Hall
机构
[1] University of Leeds,Medical Research Council Bioinformatics Centre, Leeds Institute of Cardiovascular and Metabolic Medicine
[2] Leeds General Infirmary,Department of Cardiology
[3] Vanderbilt University Medical Center,Department of Medicine
[4] University of Ferrara,Centro Cardiologico Universitario e and LTTA Centre
[5] ES Health Science Foundation,Maria Cecilia Hospital, GVM Care and Research
[6] University of Toronto,Department of Medicine
[7] Leeds General Infirmary Old Site,undefined
来源
Systematic Reviews | / 7卷
关键词
Angiotensin-converting enzyme inhibitors; Angiotensin receptor blockers; Hypertension; Blood pressure; Heart failure; Myocardial infarction; Mortality; Clinical outcomes;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 126 条
[1]  
Dawber TR(1957)Coronary heart disease in the Framingham study Am J Public Health Nations Health 47 4-24
[2]  
Moore FE(1965)Vascular disease of the brain -- epidemiologic aspects: the Framingham study Am J Public Health Nations Health 55 1355-1366
[3]  
Mann GV(1996)The progression from hypertension to congestive heart failure JAMA 275 1557-1562
[4]  
Kannel WB(2000)Systolic blood pressure and mortality Lancet (London, England) 355 175-180
[5]  
Dawber TR(2016)Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis Lancet (London, England) 387 957-967
[6]  
Cohen ME(2016)Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement Medicine 95 e4071-2097
[7]  
McNamara PM(2012)Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients Eur Heart J 33 2088-2090
[8]  
Levy D(2017)Angiotensin receptor blockers do not reduce risk of myocardial infarction, cardiovascular death, or total mortality: further evidence for the ARB-MI paradox Circulation 135 2088-2087
[9]  
Larson MG(2017)Angiotensin receptor blockers reduce cardiovascular events, including the risk of myocardial infarction Circulation 135 2085-60
[10]  
Vasan RS(2016)Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials Mayo Clin Proc 91 51-2031